Characterization of the Minimalist Hybrid Protein Inhibitor ME47 as a Potential Anti-tumour Agent Designed to Target Myc Activity in Cancer
Effective therapeutics are urgently needed to improve the treatment and survival of cancer patients and we believe that targeting the MYC oncogene would fill this gap. Our strategy to achieve this goal involves the design of minimalist hybrid protein inhibitors (MHP) - 25-75 amino acid proteins comp...
Main Author: | Lustig, Lindsay |
---|---|
Other Authors: | Penn, Linda Z. |
Language: | en_ca |
Published: |
2013
|
Subjects: | |
Online Access: | http://hdl.handle.net/1807/35641 |
Similar Items
Estrategia Comercial Internacional 2-AN47-200902
by: Maekawa Miyasato Cesar Daniel
Published: (2020)
by: Maekawa Miyasato Cesar Daniel
Published: (2020)
Estrategia Comercial Internacional 2-AN47-201001
by: Maekawa Miyasato Cesar Daniel
Published: (2020)
by: Maekawa Miyasato Cesar Daniel
Published: (2020)
Similar Items
-
Characterization of the Minimalist Hybrid Protein Inhibitor ME47 as a Potential Anti-tumour Agent Designed to Target Myc Activity in Cancer
by: Lustig, Lindsay
Published: (2013) -
Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc
by: Daniel Massó-Vallés, et al.
Published: (2020-04-01) -
Identification and Functional Characterization of Novel MYC-Regulated Long Noncoding RNAs in Group 3 Medulloblastoma
by: Jessica Rea, et al.
Published: (2021-07-01) -
RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"
by: Bryan Oronsky, et al.
Published: (2020-01-01) -
The Molecular ‘Myc-anisms’ Behind Myc-Driven Tumorigenesis and the Relevant Myc-Directed Therapeutics
by: Jessica McAnulty, et al.
Published: (2020-12-01)